Kidney function changes and their relation with the progression of cerebral small vessel disease and cognitive decline.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 03 10 2019
revised: 27 11 2019
accepted: 12 12 2019
pubmed: 24 12 2019
medline: 20 3 2021
entrez: 24 12 2019
Statut: ppublish

Résumé

We aimed to study whether worsening in markers of kidney function parallels the progression in cerebral small vessel disease (cSVD) and cognitive decline. Data from the ISSYS (Investigating Silent Strokes in Hypertensives Study), a longitudinal population-based study in hypertensives aged 50-70 and dementia and stroke-free at baseline. At both visits, patients underwent a brain MRI, a cognitive diagnosis (normal aging or mild cognitive impairment, [MCI]) and urine and blood sampling collection. We assessed the incidence of infarcts and cerebral microbleeds, and the progression of white matter hyperintensities at periventricular (PVH) and deep areas. We determined changes in albumin-creatinine ratio and estimated glomerular filtration rate (eGFR). These changes were dichotomized into microalbuminuria at follow-up -either in subjects with or without baseline microalbuminuria- and significant decline in eGFR -lowest quintile of eGFR change (-10.57 mL/min/1.73m 360 patients were followed-up for 4 years. 80 (23%) patients presented microalbuminuria at follow-up and 68 (20.1%) experienced a significant eGFR decline. Considering cSVD change, we found a relationship between microalbuminuria at follow-up and progression in PVH (β = 0.31, P-value = .01). Regarding cognitive decline, presence of microalbuminuria at follow-up related to a steeper decrease in memory function (β = -0.36, P-value<.01). Moreover, patients with significant decline in eGFR were at higher risk of incident MCI (OR = 3.54, P-value = .02). These associations were independent of progression of cSVD. The worsening in markers of kidney function paralleled the decrease in cognition and the progression of cSVD, and this may be explained by common shared underlying risk factors.

Identifiants

pubmed: 31869590
pii: S0022-510X(19)32400-1
doi: 10.1016/j.jns.2019.116635
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

116635

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest We declare no conflicts of interest.

Auteurs

Joan Jiménez-Balado (J)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain. Electronic address: joan.balado@gmail.com.

Iolanda Riba-Llena (I)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain. Electronic address: iriba2010@gmail.com.

Jesús Pizarro (J)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain. Electronic address: jesus.pizarro@vhir.org.

Antoni Palasí (A)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Dementia Unit, Neurology Service, Barcelona, Spain. Electronic address: toni.palasi@gmail.com.

Anna Penalba (A)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain. Electronic address: anna.penalba@gmail.com.

Clara Ramírez (C)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Biochemistry Lab, Clinical Central Laboratories, Barcelona, Spain. Electronic address: clramire@vhebron.net.

Olga Maisterra (O)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain. Electronic address: omaiste@hotmail.com.

Eugenia Espinel (E)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Nephrology, Hypertension Unit, Barcelona, Spain. Electronic address: eespinel@vhebron.net.

Natalia Ramos (N)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Nephrology, Hypertension Unit, Barcelona, Spain. Electronic address: nramos@vhebron.net.

Francesc Pujadas (F)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Dementia Unit, Neurology Service, Barcelona, Spain. Electronic address: fpujadas@vhebron.net.

Daniel Serón (D)

Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Nephrology, Hypertension Unit, Barcelona, Spain. Electronic address: dseron@vhebron.net.

Pilar Delgado (P)

Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Neurovascular Research Lab, Barcelona, Spain; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Dementia Unit, Neurology Service, Barcelona, Spain. Electronic address: pilar.delgado@vhir.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH